My interest in gene therapy began during my Ph.D. with Pr. Nicolas Levy (University La Timone Medical School Marseille, France). I initiated a highly translational project encompassing innovative RNA-based adeno-associated viral vector (AAV) gene therapy approaches for limb-girdle muscular dystrophy. In 2011, I accepted a postdoctoral position in Dr. Flanigan's lab at NCH working on gene therapy for Duchenne Muscular Dystrophy (DMD). My work led to the identification of a novel internal ribosome entry site (IRES) within the DMD gene. Based on these exciting findings, we developed a therapeutic approach using vectorized exon skipping (VES). Since July 2016, my lab has pursued three major areas of research: 1.VES gene therapy for DMD; 2.Development of VES gene therapy for Myotonic Dystrophy type 1; 3.Developing gene therapy for novel neurological diseases (SCN2A and IRF2BPL mutation related diseases).
Abigail Wexner Research Institute at Nationwide Children's Hospital
Columbus, Ohio, USA